Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology, Inc. (Nasdaq: VIR) will host a virtual Hepatitis Portfolio R&D Day on April 27, 2022, from 12:00 – 2:00 p.m. ET. The event aims to showcase the company's hepatitis pipeline and clinical advancements for 2022. Key presentations will be made by senior leaders, including George Scangos, Phil Pang, and Carey Hwang, along with a hepatitis treatment overview by Dr. Jordan Feld. Participants can register and access a live webcast on Vir's website, which will be available for 30 days post-event.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced that its scientists won the Pediatric COVID-19 Data Challenge, organized by BARDA and HHS. They developed a machine learning model to identify severe outcomes in pediatric COVID-19 patients using a dataset from over 116,000 pediatric outpatients. The award included a $200,000 prize, showcasing Vir’s commitment to leveraging AI for healthcare improvements. CEO George Scangos highlighted the significance of this achievement in enhancing patient care and pandemic preparedness.
Vir Biotechnology, Inc. (Nasdaq: VIR) will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on April 11, 2022, at 11:00 a.m. ET. The conference will be held virtually, and investors can access a live webcast of the discussion on the Vir website under the Events & Presentations section. The recording will be available for 30 days. Vir Biotechnology focuses on leveraging immunologic insights and technology to combat serious infectious diseases, with a development pipeline that includes COVID-19, hepatitis B virus, influenza A, and HIV.
Vir Biotechnology and GlaxoSmithKline announced that the FDA amended the Emergency Use Authorization for sotrovimab, indicating its 500 mg dose is unlikely to work against the Omicron BA.2 variant. The companies are preparing data to support a higher dose and will engage with global health authorities. The FDA's update excludes sotrovimab in areas where infections are likely due to non-susceptible variants. Sotrovimab remains authorized in various countries, but its usage is limited based on variant susceptibility and hospitalizations related to COVID-19.
Vir Biotechnology will participate in a panel discussion on infectious diseases at the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 10:30 a.m. ET. The event will be held virtually, and a live webcast can be accessed through the Investors section of the Vir website, where it will also be archived for 30 days.
Vir Biotechnology focuses on developing treatments for serious infectious diseases using innovative immunologic technologies. Its pipeline includes candidates for COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology reported transformative advancements in its fourth quarter and full-year 2021 results, revealing a substantial collaboration revenue of $917.2 million from the sale of sotrovimab, with 1.7 million doses sold globally to date. The company anticipates an additional $1.1 billion in revenue from contracts for upcoming deliveries in early 2022. Efforts for various ongoing trials regarding hepatitis B, HIV, and flu treatments are also highlighted, alongside a strong cash position of approximately $909.5 million, providing flexibility for future investments.
Vir Biotechnology, Inc. (Nasdaq: VIR) will provide a corporate update and report its financial results for Q4 and full year 2021 on February 24, 2022. The update will include insights into the company’s performance and is expected to be accessible on its website post-market close. Vir specializes in immunology, focusing on serious infectious diseases, using four technology platforms designed to enhance the immune system. Its pipeline includes candidates targeting COVID-19 and other infectious diseases.
Vir Biotechnology has announced that preclinical data shows its investigational monoclonal antibody, sotrovimab, retains neutralizing activity against the BA.2 subvariant of Omicron. This data will be shared with global regulatory authorities, with publication expected soon. Sotrovimab is authorized for emergency use in the US and has been granted conditional marketing authorizations in several countries, including the EU and Australia. Despite recent findings suggesting some antibodies are ineffective against certain variants, Vir maintains sotrovimab's efficacy.
Vir Biotechnology announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, effective March 2, 2022. With 25 years of global commercial experience, Friedl-Naderer will drive portfolio strategy and business development. Previously, she held leadership roles at Biogen, focusing on groundbreaking treatments for neurological conditions. Her expertise is expected to enhance Vir's growth and patient access to its products aimed at serious infectious diseases.
Vir Biotechnology has expanded its partnership with the Bill & Melinda Gates Foundation, focusing on novel "vaccinal antibody" technology aimed at treating HIV and preventing malaria. This initiative includes a $40 million equity investment and a $10 million grant to support clinical trials evaluating the antibodies' effectiveness. CEO George Scangos emphasized the importance of this collaboration in addressing global infectious diseases. The funding will enhance Vir's pipeline targeting serious conditions like COVID-19 and hepatitis B, aiming for significant public health advancements.